Kinoxis Therapeutics

Kinoxis Therapeutics is a Melbourne biotech spun out of the University of Sydney in 2017, developing treatments for agitation and aggression in dementia. Its lead candidate KNX100 is in a Phase 2 trial that has reached half its recruitment target, with results expected in mid-2027, and in September 2026 it raised A$6.75 million led by Main Sequence plus a A$2.5 million government grant.

Company Facts

• Headquarters: Melbourne, Australia
• Founded: 2017
• Type: startup
• Website: https://kinoxistherapeutics.com
• Industries: Biotechnology, Pharmaceuticals, Health Care